PATENT CLAIM ANALYSIS

Application Number: 16211743
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-10
Patent Classification: ["424", "093450"]

Abstract:
This invention relates to new uses of  Bifidobacteria  (particularly, although not exclusively, probiotic  Bifidobacteria ), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

Claim (Index 79):
The method of  claim 64 , wherein the antidiabetic drug is a dipeptidyl peptidase-4 (DPP-4) inhibitor or a biguanide.

Metadata:
- Claim Count in Document: 104.0
- Percentile: 98.0
- Lexical Diversity: 1.46429
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13384748', '14983827', '15744211', '14457916', '15565317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7997257373597385
- 35 USC 102 Novelty (BERT): 0.5541830632973017
- Combined Prediction Score: 0.7751714699534948
- Mean Citation Score: 413.4368759999999
- Max Citation Score: 519.724
- Similarity Product: 273.18695454144483

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test